Inovio Pharmaceuticals (INO)
Develops DNA medicines and CELLECTRA devices, led by INO-3107 for recurrent respiratory papillomatosis.
Something off on this page? Send us feedback.
Develops DNA medicines and CELLECTRA delivery devices for a clinical-stage pipeline in HPV-related diseases, cancer and infectious diseases. INO-3107 for recurrent respiratory papillomatosis is the lead regulatory program, with additional financing needed for development beyond it and future commercialization.
Develops DNA medicines for HPV-related diseases, cancer and infectious diseases, using investigational CELLECTRA devices to deliver DNA into cells. The platform is designed to generate T-cell responses and may also support monoclonal-antibody production and protein expression. These programs remain a development platform and pipeline, rather than established product sales.
INO-3107, an investigational treatment for adults with recurrent respiratory papillomatosis, is the lead regulatory program; its biologics license application is under FDA review for accelerated approval. FDA has identified a potential issue regarding the information supporting eligibility for that pathway, while further development beyond INO-3107 and any future commercialization require additional financing.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 13, 2026 | Jefferies | Upgrade | Target: — | Target: $3 |
| Jun 1, 2026 | H.C. Wainwright | Target | Target: — | Target: $2.50 |
| Nov 14, 2025 | Piper Sandler | Reiterate | Rating: —Target: — | Target: $6 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $36.7M · Total debt $8.0M · Total assets $49.4M · Shareholders' equity $4.4M
- Revenue
- $0
- Operating income
- −$18.6M
- Net income
- −$6.0M
No dividends on record.
| Institutions | ≈ 49.43% | 34.16M shares | |
|---|---|---|---|
| 112 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.56% | 389.8K shares | |
| 11 holders · as of May 21, 2026 | |||
| Strategic holders | 18.61% | 12.86M shares | |
| 2 holders · as of May 15, 2026 | |||
| Other | ≈ 31.40% | 21.69M shares | |
| remainder | |||
69.09M company shares as of Sep 7, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (103.40M in the company's Sep 23, 2026 report, 69.09M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
RA Capital Management, L.P.Institution | 15.44% | 10.67M | filed Aug 7, 2026 |
FMR LLCInstitution | 12.24% | 8.45M | as of Jun 30, 2026 |
Janus Henderson Group PLCStrategic | 9.65% | 6.67M | filed Dec 8, 2025 |
Highbridge Capital Management LLCStrategic | 8.96% | 6.19M | filed May 15, 2026 |
Jupiter Topco LLCInstitution | 7.48% | 5.17M | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Precigen
FDA-approved adult RRP therapy with HPV cancer programs
- PDS Biotechnology
Pivotal HPV16-positive head-and-neck cancer immunotherapy
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | $1.25 | −3.47% | $89.1M | — | — | — | — |
| Precigen | $7.49 | −5.07% | $2.81B | — | 14.3 | 32.8 | +6,161.7% |
| PDS Biotechnology | $0.8448 | −7.16% | $50.9M | — | — | — | — |
| Median | — | 14.3 | 32.8 | +6,161.7% |